BioNTech SE Statistics
Total Valuation
BioNTech SE has a market cap or net worth of $21.82 billion. The enterprise value is $6.00 billion.
Important Dates
The last earnings date was Tuesday, March 10, 2026, before market open.
| Earnings Date | Mar 10, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
BioNTech SE has 251.33 million shares outstanding. The number of shares has increased by 0.54% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 251.33M |
| Shares Change (YoY) | +0.54% |
| Shares Change (QoQ) | +2.02% |
| Owned by Insiders (%) | 18.38% |
| Owned by Institutions (%) | 21.93% |
| Float | 93.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 6.47 |
| Forward PS | 9.66 |
| PB Ratio | 0.97 |
| P/TBV Ratio | 1.08 |
| P/FCF Ratio | 66.97 |
| P/OCF Ratio | 40.75 |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 1.78 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | 18.41 |
Financial Position
The company has a current ratio of 7.54, with a Debt / Equity ratio of 0.01.
| Current Ratio | 7.54 |
| Quick Ratio | 6.87 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | n/a |
| Debt / FCF | 0.96 |
| Interest Coverage | -89.20 |
Financial Efficiency
Return on equity (ROE) is -5.88% and return on invested capital (ROIC) is -25.47%.
| Return on Equity (ROE) | -5.88% |
| Return on Assets (ROA) | -3.56% |
| Return on Invested Capital (ROIC) | -25.47% |
| Return on Capital Employed (ROCE) | -6.38% |
| Weighted Average Cost of Capital (WACC) | 12.57% |
| Revenue Per Employee | $431,614 |
| Profits Per Employee | -$170,862 |
| Employee Count | 7,807 |
| Asset Turnover | 0.13 |
| Inventory Turnover | 3.10 |
Taxes
In the past 12 months, BioNTech SE has paid $100.15 million in taxes.
| Income Tax | 100.15M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -8.99% in the last 52 weeks. The beta is 1.53, so BioNTech SE's price volatility has been higher than the market average.
| Beta (5Y) | 1.53 |
| 52-Week Price Change | -8.99% |
| 50-Day Moving Average | 104.84 |
| 200-Day Moving Average | 104.10 |
| Relative Strength Index (RSI) | 34.22 |
| Average Volume (20 Days) | 1,789,990 |
Short Selling Information
The latest short interest is 4.46 million, so 4.34% of the outstanding shares have been sold short.
| Short Interest | 4.46M |
| Short Previous Month | 4.72M |
| Short % of Shares Out | 4.34% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 6.86 |
Income Statement
In the last 12 months, BioNTech SE had revenue of $3.37 billion and -$1.33 billion in losses. Loss per share was -$5.52.
| Revenue | 3.37B |
| Gross Profit | 2.65B |
| Operating Income | -1.49B |
| Pretax Income | -1.23B |
| Net Income | -1.33B |
| EBITDA | -1.32B |
| EBIT | -1.49B |
| Loss Per Share | -$5.52 |
Full Income StatementBalance Sheet
The company has $16.13 billion in cash and $313.96 million in debt, with a net cash position of $15.82 billion or $62.94 per share.
| Cash & Cash Equivalents | 16.13B |
| Total Debt | 313.96M |
| Net Cash | 15.82B |
| Net Cash Per Share | $62.94 |
| Equity (Book Value) | 22.57B |
| Book Value Per Share | 89.81 |
| Working Capital | 16.44B |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $535.40 million and capital expenditures -$205.59 million, giving a free cash flow of $325.78 million.
| Operating Cash Flow | 535.40M |
| Capital Expenditures | -205.59M |
| Depreciation & Amortization | 165.38M |
| Net Borrowing | -59.03M |
| Free Cash Flow | 325.78M |
| FCF Per Share | $1.30 |
Full Cash Flow StatementMargins
Gross margin is 78.70%, with operating and profit margins of -44.14% and -39.59%.
| Gross Margin | 78.70% |
| Operating Margin | -44.14% |
| Pretax Margin | -36.61% |
| Profit Margin | -39.59% |
| EBITDA Margin | -39.17% |
| EBIT Margin | -44.14% |
| FCF Margin | 9.67% |
Dividends & Yields
BioNTech SE does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -0.54% |
| Shareholder Yield | -0.54% |
| Earnings Yield | -6.11% |
| FCF Yield | 1.49% |
Dividend DetailsAnalyst Forecast
The average price target for BioNTech SE is $134.15, which is 54.53% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $134.15 |
| Price Target Difference | 54.53% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 13 |
| Revenue Growth Forecast (5Y) | 5.47% |
| EPS Growth Forecast (5Y) | -19.33% |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
BioNTech SE has an Altman Z-Score of 6.72 and a Piotroski F-Score of 4.
| Altman Z-Score | 6.72 |
| Piotroski F-Score | 4 |
